Rabbit anti EGF R (L858R mutant) antibody
recognizes epidermal growth factor receptor (EGF R), also known as ERBB1 and HER1, mutated at the residue L858R.
EGF R is a member of the ErbB family of receptor tyrosine kinases (RTKs) involved with activation of multiple signaling pathways including Ras/MAPK, PI3K/AKT, and PKC signaling (Sigismund et al. 2018
). The EGF R plasma membrane receptor achieves this effect by binding to a range of extracellular growth factors, undergoing a conformational change, and transducing intracellular signaling (Liu et al. 2017
). EGF R was one of the first identified oncogenes, and overexpression of EGF R has been reported in many human malignancies. The EGF R inhibitors gefitinib and erlotinib are used for treatment of advanced non-small cell lung cancer (NSCLC) (Bethune et al. 2010
). The L858R activating mutation is a single-point substitution mutation in EGF R and is common in NSCLC. It is associated with decreased sensitivity to gefitinib and erlotinib (Gazdar, 2010
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of EGF R (L858R Mutant) antibody
|Immunohistology - Paraffin
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.